BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Investor Relations
Stock price graph

We are a clinical-stage nanomedicine platform company developing ACCURINS®, a new class of targeted and programmable therapeutics developed using our Medicinal Nanoengineering® platform. ACCURINS are nanoparticles designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease, enhancing efficacy while minimizing adverse effects on healthy tissues. We are developing our own pipeline of ACCURINS, initially in oncology, as well as ACCURINS in collaboration with biopharmaceutical companies.

Our lead drug candidate, BIND-014, is currently enrolling patients with squamous histology non-small cell lung cancer (NSCLC) in a Phase 2 clinical trial called iNSITE1. We are also evaluating BIND-014 in patients with urothelial carcinoma, cholangiocarcinoma, cervical cancer and squamous cell carcinoma of the head and neck in a second Phase 2 trial called iNSITE2. Our second proprietary drug candidate, BIND-510, is a prostate-specific membrane antigen (PSMA)-targeted ACCURIN nanoparticle containing vincristine and is currently in preclinical development. The company has collaborated or is collaborating with Pfizer, AstraZeneca, Roche, Merck, Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals, Inc.) and Amgen to develop ACCURINS based on therapeutic payloads and targeting ligands from their product pipelines.

View all »   RSSRecent Releases

Feb 10, 2016
AZD2811 ACCURINS® Data Published in Science Translational Medicine Highlight One of the First Applications of Nanomedicine to Molecularly Targeted Cancer Therapies

Jan 27, 2016
BIND Therapeutics Provides Enrollment Update for Phase 2 iNSITE 1 and iNSITE 2 Trials with BIND-014

+ 0.14
Day High:
Day Low:
9:37 AM ET on Feb 11, 2016
Delayed at least 20 minutes.
Provided by eSignal.
Media Inquiries
Direct media inquiries to:
Jeff Boyle

Investor Inquiries
Direct investor inquiries to:
Tom Baker